Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Liabilities (2017 - 2025)

Historic Total Liabilities for Serina Therapeutics (SER) over the last 9 years, with Q3 2025 value amounting to $10.8 million.

  • Serina Therapeutics' Total Liabilities fell 4911.82% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 4911.82%. This contributed to the annual value of $6.2 million for FY2024, which is 2795.39% up from last year.
  • Serina Therapeutics' Total Liabilities amounted to $10.8 million in Q3 2025, which was down 4911.82% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Total Liabilities ranged from a high of $34.6 million in Q2 2023 and a low of $3.9 million during Q3 2023
  • Its 5-year average for Total Liabilities is $15.0 million, with a median of $14.3 million in 2022.
  • As far as peak fluctuations go, Serina Therapeutics' Total Liabilities crashed by 7728.62% in 2023, and later soared by 44562.48% in 2024.
  • Over the past 5 years, Serina Therapeutics' Total Liabilities (Quarter) stood at $15.0 million in 2021, then surged by 36.78% to $20.6 million in 2022, then tumbled by 76.37% to $4.9 million in 2023, then increased by 27.95% to $6.2 million in 2024, then soared by 74.05% to $10.8 million in 2025.
  • Its Total Liabilities stands at $10.8 million for Q3 2025, versus $7.3 million for Q2 2025 and $5.2 million for Q1 2025.